Active Ingredient History
Carvedilol competitively blocks β1, β2 and α1 receptors. The drug lacks sympathomimetic activity and has vasodilating properties that are exerted primarily through α1-blockade. Animal models indicate that carvedilol confers protection against myocardial necrosis, arrhythmia and cell damage caused by oxidising free radicals, and the drug has no adverse effects on plasma lipid profiles. COREG® (carvedilol) is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol is the first drug of its kind to be approved for the treatment of congestive heart failure, and is now the standard of care for this devastating disease. Carvedilol is also confirmed as effective in the management of mild to moderate hypertension and ischaemic heart disease. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Coronary Syndrome (Phase 4)
Altitude (Phase 4)
Alzheimer Disease (Phase 4)
Anesthesia and Analgesia (Phase 4)
Angina Pectoris (Phase 4)
Angina, Stable (Phase 4)
Anxiety (Phase 2)
Arthritis, Rheumatoid (Early Phase 1)
Ascites (Phase 4)
Asthma (Phase 4)
Atrial Fibrillation (Phase 4)
Bariatric Surgery (Phase 4)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 3)
Cancer Survivors (Phase 2)
Cardiomyopathies (Phase 4)
Cardiomyopathy, Dilated (Phase 4)
Cardiotoxicity (Phase 3)
Cardiovascular Abnormalities (Phase 2)
Cardiovascular Diseases (Phase 4)
Carvedilol (Phase 4)
Chagas Cardiomyopathy (Phase 4)
Cocaine-Related Disorders (Phase 2)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Endothelium (Phase 4)
Epilepsy (Phase 2/Phase 3)
Esophageal and Gastric Varices (Phase 4)
Essential Hypertension (Phase 3)
Fasting (Phase 1)
Fibrosis (Phase 4)
Fontan Procedure (Phase 4)
Gastric Bypass (Phase 4)
Glioblastoma (Early Phase 1)
Healthy Volunteers (Phase 1)
Heart Disease Risk Factors (Phase 1)
Heart Diseases (Phase 1)
Heart Failure, Diastolic (Phase 4)
Heart Failure, Systolic (Phase 4)
Heart Ventricles (Phase 4)
Hematopoietic Stem Cell Transplantation (Phase 3)
Hemorrhage (Phase 4)
Hepatic Encephalopathy (Phase 4)
Hepatitis B (Phase 3)
Hepatitis C, Chronic (Phase 3)
Hypertension ()
Hypertension, Portal (Phase 4)
Hypertension, Pulmonary (Phase 2)
Hypertrophy, Left Ventricular (Phase 3)
Hypoglycemia (Phase 2)
Hypoxia (Phase 4)
Kidney Diseases (Phase 2)
Kidney Failure, Chronic (Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Liver Cirrhosis (Phase 4)
Lymphoma (Phase 3)
Magnetic Resonance Imaging (Phase 2)
Masked Hypertension (Phase 4)
Metabolic Diseases (Phase 1)
Multiple Myeloma (Phase 3)
Muscular Dystrophy, Duchenne (Phase 4)
Myocardial Infarction (Phase 4)
Neoplasms (Phase 4)
Non-ST Elevated Myocardial Infarction (Phase 4)
Obesity (Phase 4)
Obesity, Abdominal (Phase 3)
Parkinson Disease (Phase 2)
Parkinson Disease, Secondary (Phase 2)
Peritonitis (Phase 4)
Prehypertension (Phase 1/Phase 2)
Prostatic Neoplasms (Phase 2)
Pulmonary Arterial Hypertension (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Recurrence (Phase 2)
REM Sleep Behavior Disorder (Phase 2)
Renal Dialysis (Phase 4)
Sarcoma (Phase 2)
Sleep (Early Phase 1)
Sleep Deprivation (Early Phase 1)
Sleep Wake Disorders (Early Phase 1)
Smoking (Phase 2)
Sprains and Strains (Phase 4)
ST Elevation Myocardial Infarction (Phase 4)
Stress Disorders, Post-Traumatic (Phase 2)
Substance-Related Disorders (Phase 2)
Tricuspid Valve Insufficiency (Phase 3)
Ventricular Dysfunction, Left (Phase 4)
Ventricular Outflow Obstruction (Phase 4)
Ventricular Premature Complexes (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
